CN1403140A - Medicine for treating acute and chronic hepatitis B - Google Patents

Medicine for treating acute and chronic hepatitis B Download PDF

Info

Publication number
CN1403140A
CN1403140A CN02138431A CN02138431A CN1403140A CN 1403140 A CN1403140 A CN 1403140A CN 02138431 A CN02138431 A CN 02138431A CN 02138431 A CN02138431 A CN 02138431A CN 1403140 A CN1403140 A CN 1403140A
Authority
CN
China
Prior art keywords
medicine
radix
hepatitis
virus
chronic hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN02138431A
Other languages
Chinese (zh)
Other versions
CN1169570C (en
Inventor
季长春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB021384312A priority Critical patent/CN1169570C/en
Publication of CN1403140A publication Critical patent/CN1403140A/en
Application granted granted Critical
Publication of CN1169570C publication Critical patent/CN1169570C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The medicine for treating acute and chronic hepatitis B is prepared with 11 kinds of Chinese medicinal materials including pseudostellaria root, trogopterus dung, red sage, chicken's gizzard membrane, taraxacum, etc. The medicine can regulate immunological cell and liver function, excite body to produce interferon to inhibit the virus replication inside the liver, killing virus gene HBV-DNA to inhibit re-combination of hepatitis B virus and promote blood circulation to eliminate blood stasis. It has stable curative effect and no any toxic side effect. It has also high curative effect on early stage hepatocirrhosis.

Description

The medicine of treatment acute or chronic hepatitis B
Technical field
The present invention relates to a kind of medicine for the treatment of acute or chronic hepatitis B, specifically is the Chinese patent medicine of feedstock production with the Chinese herbal medicine.
Background technology
China is hepatitis big country, and hepatitis b virus carrier accounts for the 10-20% of total population, and wherein 25% is chronic hepatitis B patient, sends out the patient based on person between twenty and fifty.Along with the unban population increase in density, the degree of crowding day by day increases, and the chance that hepatitis is propagated is more, and the sickness rate of hepatitis is higher.Chronic hepatitis B is a kind of chronic, infectious disease that is caused by hepatitis B virus (HBV), and serious harm health influences quality of life.Chronic hepatitis B is a kind of commonly encountered diseases, frequently-occurring disease.Can be divided into according to hepatitis B surface antigen (HBsAg) carrying rate: high popular district (>8%), in popular district (2%-7%), low popular district (<2%).China is one of high popular district.According to statistics, the present hepatitis B virus infection rate of China overview is: anti-HBc and/or anti-HBs positive person are about 60%; Non-infection population accounts for 26%; Chronic hepatitis B reaches 2%; The male chronic asymptomatic HBsAg carrier of HBsAg is 10%; The chronic asymptomatic HBV carrier of HBsAg feminine gender is 2%.This shows that the popular situation of China's hepatitis B is very severe.At present in the drug market, the medicine the most in fashion of treatment hepatitis B is " lamivudine-heptodin ", but its defective be bounce soon, virus variation easily starts an inflammation of the liver; Interferon is arranged again, and its defective is that negative conversion rate is low, and a few peoples can cause that the paddy third ammonia enzyme raises, and patient is difficult to accept.
Summary of the invention
The technical problem to be solved in the present invention is, proposed a kind of respond well medicine of acute or chronic hepatitis B for the treatment of, and it is to the big and small three Yang negative conversion rate height of hepatitis B patient, and is without any side effects.
Hepatitis B is current national brainstorm project, and Western medicine still can't thoroughly solve, but Chinese medicine gets a good chance of.Causing the reason that disease can not rehabilitation mainly is that human body is weakened body resistance, autoimmune function is low, can not resist, dispel virus, and some human autoimmune is regulated disorderly in addition, or incoordination of seven emotions or battalion food do not save, or drink or tired or sexual strain all can increase the weight of the prolonged of the state of an illness and do not heal.The opinion of disease such as ancient times many well-known doctor Dui Yu lumps in the chest and abdomen, yellow dawn, tympanites is controlled, can be the hepatitis B of today summary wherein.Temperature, clear, disappear, benefit, antiperspirant, tell, down and method of treatment a lot, " life-gate theory ", " Treatise on the spleen and stomach " main benefit are more arranged, the argument of " antiperspirant, tell, down " main attack, and the inventor conscientiously learns to the sage of the past, gets its length, and in conjunction with modern medicine theory and clinical practice, with treatment must aim at the pathogenesis of disease, strengthening vital QI to eliminate pathogenic factors is a principle, adopts flat filling blood and stops up stagnant, heat-clearing and toxic substances removing and not absurd throwing bitter cold, blood circulation promoting and dispersing pathogen accumulation and the general plan of gently sending an expedition against, and prescription forms.
The technical problem to be solved in the present invention is achieved through the following technical solutions, and a kind of medicine for the treatment of acute or chronic hepatitis B is characterized in that it is the medicament of being made by following weight proportioning raw material:
Radix Pseudostellariae 15~25, Oletum Trogopterori 8~12, Radix Salviae Miltiorrhizae 6~10, Carnis Gallus domesticus gold 6~8, Herba Taraxaci 10~15, the Radix Astragali 20~30, Herba Artemisiae Scopariae 25~30, Radix Glycyrrhizae 10~12, Fructus Aurantii 5~8, Radix Angelicae Sinensis 10~15, Radix Rehmanniae Preparata 12~20.
The technical problem to be solved in the present invention can also further be reached by following technical scheme, and the optimum weight of medicine of the present invention (part) proportioning is:
Radix Pseudostellariae 20, Oletum Trogopterori 8, Radix Salviae Miltiorrhizae 6, Carnis Gallus domesticus gold 6, Herba Taraxaci 10, the Radix Astragali 20, Herba Artemisiae Scopariae 30, Radix Glycyrrhizae 10, Fructus Aurantii 5, Radix Angelicae Sinensis 10, Radix Rehmanniae Preparata 12.
The technical problem to be solved in the present invention can also further be reached by following technical scheme, and the said medicament of the present invention is a said dosage form on any pharmaceutics.
The technical problem to be solved in the present invention can also further be reached by following technical scheme, and the said medicament of the present invention is a decoction.
As everyone knows, the pathogenic former of hepatitis B is hepatitis B virus.After hepatitis B virus is survived in hepatocyte, is duplicated.Be discharged in the blood again, thus viral high load capacity in the blood flow not only, and also most of hepatocyte of liver are all infected.HBV itself does not directly cause hepatocellular pathological changes, just survives in hepatocyte, duplicates, and the antigen presentation that it duplicated is on liver plasma membrane, and the immune system of exciting human is recognized, and cleaning reaction is taken place.But behind the human infection hepatitis B virus, because the body's immunity difference, thereby course of disease development is also different.If body's immunological function is sound, the immune system back identification hepatitis B virus that is activated is attacked the hepatocyte of infective virus and is removed it; If body's immunological function is activated, but be in low state, body is attacked repeatedly to the hepatocyte of infective virus, but can not remove it fully again, causes the hepatic tissue chronic inflammatory disease to be shown effect repeatedly, Here it is chronic viral hepatitis B; If body's immunological function is in tolerance status, can not discern hepatitis B virus, therefore do not attack the hepatocyte of infective virus, virus and human body " peaceful coexistence ", Here it is hepatitis B virus carriers.Hepatitis B virus infection person state of an illness difference, Therapeutic Method also is different.Acute hepatitis b should early be found, early treatment is main to the Supporting Therapy of suiting the medicine to the illness, and fully has a rest, and reasonable diet is avoided tobacco and wine, and avoiding PD is hepatitis gravis or chronic hepatitis; Chronic viral hepatitis B, the treatment measure comprises antiviral therapy, immune modulating treatment, psychology, symptomatic treatment etc.Think at present,, continue development and may cause liver cirrhosis and HBV dependency hepatocarcinoma, so antiviral therapy is the key for the treatment of chronic hepatitis B because the persistent infection of virus causes the hepatitis chronicity.The purpose for the treatment of chronic hepatitis B is: 1) suppress virus replication, promote virus sweep; 2) alleviate liver inflammation and necrosis, promote hepatocyte to repair; 3) prevention or delay of progression are liver cirrhosis; 4) incidence rate of minimizing HBV dependency hepatocarcinoma; 5) improve quality of life of patient, prolong life cycle; 6) alleviate, alleviate clinical symptoms.
Side's medicine of the present invention, wherein Radix Pseudostellariae, Radix Rehmanniae Preparata fill blood, and strengthen the liver cell regeneration ability, repair hepatic injury, strengthen human leukocytes and immunologic function; The Radix Astragali can promote human body to produce interferon simply, and strong inhibition hepatitis B virus and HBV-DNA duplicate; Herba Artemisiae Scopariae, Herba Taraxaci all have the effect of good detoxifcation, antiinflammatory, depressed liver-energy dispersing and function of gallbladder promoting; Radix Glycyrrhizae is rich in glycyrrhizin, falls enzyme and has better effect; Adapted Radix Salviae Miltiorrhizae, Fructus Aurantii, Oletum Trogopterori, Radix Angelicae Sinensis dispersing the stagnated live-QI to relieve the stagnation of QI, blood circulation promoting and blood stasis dispelling is just accord with " interior warp " institute cloud: the meaning of " liver preferring free activity ".The same usefulness of all medicines can reach every index of recovering liver function, removes hepatitis B virus gene HBV-DNA, promotes HBsAg, HBeAg sun to turn out cloudy.
Side's medicine of the present invention can be by the Chinese medicine conventional method through being decocted in water for oral dose, and be three to six months a course of treatment, do not have taboo, the patient taken other medicines simultaneously do not have influence.
Side's medicine of the present invention shows through clinical practice for many years, and square medicine is taken course of treatment of our medicine continuously, and the HBsAg negative conversion rate is 50%, the HBeAg negative conversion rate is 85%, the HBV-DNA negative conversion rate is 90%, and the liver function recovery natural rate of interest is 96%.There is 10% patient not produce the cloudy sun that changes of anti-HBS for many years more again, obtains immunity (antibody).Take side's medicine of the present invention, 1, regulate immunocyte and liver function; 2, human activin produces interferon, causes the virus replication difficulty of liver inside; 3, kill virus gene HBV-DNA makes and is difficult to make up new hepatitis B virus, without any side effects and stable curative effect in the liver; 4, blood circulation promoting and dispersing pathogen accumulation.Especially good to the early stage liver cirrhosis therapeutic effect, take six months after, total effective rate is 98%.
The specific embodiment
Embodiment 1, takes by weighing raw material by following proportioning:
Radix Pseudostellariae 20g, Oletum Trogopterori 8g, Radix Salviae Miltiorrhizae 6g, Carnis Gallus domesticus gold 6g,
Herba Taraxaci 10g, Radix Astragali 20g, Herba Artemisiae Scopariae 30g, Radix Glycyrrhizae 10g,
Fructus Aurantii 5g, Radix Angelicae Sinensis 10g, Radix Rehmanniae Preparata 12g.
This is one pair of medicine, by the Chinese medicine conventional method through being decocted in water for oral dose.
The present invention extracts its effective ingredient after also can decocting
The present invention also can clean, dries, concoct post-treatment and become powder at crude drug, dress up capsule by above-mentioned crude drug dosage and take.In addition, the present invention extracts its effective ingredient after also can decocting, and makes dissolved granule and takes.
Embodiment 2, take by weighing raw material by following proportioning:
Radix Pseudostellariae 15g, Oletum Trogopterori 10g, Radix Salviae Miltiorrhizae 8g, Carnis Gallus domesticus gold 7g,
Herba Taraxaci 12g, Radix Astragali 25g, Herba Artemisiae Scopariae 28g, Radix Glycyrrhizae 11g,
Fructus Aurantii 6g, Radix Angelicae Sinensis 12g, Radix Rehmanniae Preparata 16g.
This is one pair of medicine, by the Chinese medicine conventional method through being decocted in water for oral dose.
Embodiment 3, take by weighing raw material by following proportioning:
Radix Pseudostellariae 25g, Oletum Trogopterori 12g, Radix Salviae Miltiorrhizae 10g, Carnis Gallus domesticus gold 8g, Herba Taraxaci 15g, Radix Astragali 30g, Herba Artemisiae Scopariae 25g, Radix Glycyrrhizae 12g, Fructus Aurantii 8g, Radix Angelicae Sinensis 15g, Radix Rehmanniae Preparata 20g.This is one pair of medicine, by the Chinese medicine conventional method through being decocted in water for oral dose.

Claims (4)

1. medicine for the treatment of acute or chronic hepatitis B is characterized in that it is the medicament of being made by following weight proportioning raw material:
Radix Pseudostellariae 15~25, Oletum Trogopterori 8~12, Radix Salviae Miltiorrhizae 6~10, Carnis Gallus domesticus gold 6~8,
Herba Taraxaci 10~15, the Radix Astragali 20~30, Herba Artemisiae Scopariae 25~30, Radix Glycyrrhizae 10~12,
Fructus Aurantii 5~8, Radix Angelicae Sinensis 10~15, Radix Rehmanniae Preparata 12~20.
2. the medicine of treatment acute or chronic hepatitis B according to claim 1 is characterized in that optimum weight (part) proportioning of medicine of the present invention is:
Radix Pseudostellariae 20, Oletum Trogopterori 8, Radix Salviae Miltiorrhizae 6, Carnis Gallus domesticus gold 6,
Herba Taraxaci 10, the Radix Astragali 20, Herba Artemisiae Scopariae 30, Radix Glycyrrhizae 10,
Fructus Aurantii 5, Radix Angelicae Sinensis 10, Radix Rehmanniae Preparata 12.
3. the medicine of treatment acute or chronic hepatitis B according to claim 1 is characterized in that: the said medicament of the present invention is a said dosage form on any pharmaceutics.
4. the medicine of treatment acute or chronic hepatitis B according to claim 3 is characterized in that: the said medicament of the present invention is a decoction.
CNB021384312A 2002-10-11 2002-10-11 Medicine for treating acute and chronic hepatitis B Expired - Fee Related CN1169570C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB021384312A CN1169570C (en) 2002-10-11 2002-10-11 Medicine for treating acute and chronic hepatitis B

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB021384312A CN1169570C (en) 2002-10-11 2002-10-11 Medicine for treating acute and chronic hepatitis B

Publications (2)

Publication Number Publication Date
CN1403140A true CN1403140A (en) 2003-03-19
CN1169570C CN1169570C (en) 2004-10-06

Family

ID=4749477

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB021384312A Expired - Fee Related CN1169570C (en) 2002-10-11 2002-10-11 Medicine for treating acute and chronic hepatitis B

Country Status (1)

Country Link
CN (1) CN1169570C (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101502589B (en) * 2009-03-11 2010-10-13 张建云 Chinese and western medicinal composition containing bifendate for auxiliary treatment of hepatitis
CN103734430A (en) * 2014-01-10 2014-04-23 蒋宇杰 Health-maintenance healthcare tea for healing diseases by gene regulation
CN106421640A (en) * 2016-10-14 2017-02-22 单县领翔金银花种植合作社 Traditional Chinese medicine for curing hepatitis B in pregnancy
CN115192640A (en) * 2021-04-12 2022-10-18 牛兴旺 Traditional Chinese medicine for circularly treating viral infection

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101502589B (en) * 2009-03-11 2010-10-13 张建云 Chinese and western medicinal composition containing bifendate for auxiliary treatment of hepatitis
CN103734430A (en) * 2014-01-10 2014-04-23 蒋宇杰 Health-maintenance healthcare tea for healing diseases by gene regulation
CN106421640A (en) * 2016-10-14 2017-02-22 单县领翔金银花种植合作社 Traditional Chinese medicine for curing hepatitis B in pregnancy
CN115192640A (en) * 2021-04-12 2022-10-18 牛兴旺 Traditional Chinese medicine for circularly treating viral infection

Also Published As

Publication number Publication date
CN1169570C (en) 2004-10-06

Similar Documents

Publication Publication Date Title
CN101028507A (en) Chinese-medicinal composition for treating asthma
CN1132643A (en) Medicine for diseases of liver and gall
CN1475229A (en) Antifatigue compound Chinese medicine prescription and its preparation method
CN1698877A (en) Liver nourishing capsule with Chinese caterpillar fungus
CN1698812A (en) Pharmaceutical composition for treating hepatitis B
CN1169570C (en) Medicine for treating acute and chronic hepatitis B
CN102552512B (en) Traditional Chinese medicine used for treating hepatitis B
CN101912524B (en) Schisandra liver-benefiting capsules
CN1965979A (en) Medicament for treating hepatitis B
CN1066628C (en) Medicine for chronic hepatitis B and its preparation
CN101199749A (en) Chinese medicine for treating AIDS
CN103479835A (en) Traditional Chinese medicine for treating liver cirrhosis
CN102488851B (en) Drug for treating recurrent genital herpes and preparation method thereof
CN101618156A (en) Medicine composition for treating hepatitis B and preparation method thereof
CN102406906A (en) Traditional Chinese medicine composition for treating acute hepatitis B
CN1061885C (en) Specific infusion for hepatitis B and producing process thereof
CN1146362A (en) Capsule for anti hepatitis B
CN1340353A (en) Orally-applied medicine for treating hepatism and its preparing process
CN1943682A (en) A Chinese traditional medicinal composition for treatment of hepatitis C
CN102274438A (en) Oral powder for treating hepatitis B
CN1279074A (en) Chinese-medicinal pill 'Ganxuetong'
CN1241591C (en) Taiyi liver protection capsule and its preparing method
CN1106856C (en) Hepatosis treating medicine and its preparation
CN1085548C (en) Traditional Chinese medicinal prepns. for treating hepatitis B virus, and method for preparing same
CN1159057C (en) Medicine for treating hepatitis, and preparing process thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041006

Termination date: 20091111